GlassScriptPhysician profile
Sara Humes
NPI 1952029241
$4,774.03
in general payments reported to CMS, 2019-2025
25 companies · $737 in 2025
The $737 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $855 · 2023: $2,361 · 2024: $821 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,473 · Travel and Lodging: $315 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,473.43 |
| Travel and Lodging | $315.27 |
| Education | $130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,859.00 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $511.12 | 2023-2025 | Watchman Access System, Watchman, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $390.39 | 2023-2024 | |
| Abbott Laboratories | $255.11 | 2022-2025 | Amplatzer Amulet, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.10 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $179.55 | 2023-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $141.16 | 2023-2025 | Amvuttra |
| Bridgebio Pharma, INC. | $137.54 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $111.08 | 2023-2024 | Camzyos, Eliquis |
| Abiomed | $105.96 | 2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.63 | 2023-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $89.92 | 2022-2025 | Verquvo, Capvaxive |
| Amgen INC. | $85.59 | 2023-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $83.24 | 2023-2024 | |
| Pfizer INC. | $82.95 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $75.76 | 2024-2025 | Assure Wcd |
| Heartflow, INC. | $74.35 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $66.39 | 2022-2025 | Farxiga, Lokelma |
| Impulse Dynamics (USA) INC. | $65.91 | 2023 | Optimizer |
| Esperion Therapeutics, INC. | $55.75 | 2024-2025 | Nexletol |
| Medtronic, INC. | $46.94 | 2023-2025 | Corevalve Evolut R |
| Cvrx, INC. | $27.54 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $17.00 | 2023 | Arcalyst |
| Exact Sciences Corporation | $15.79 | 2025 | Cologuard Collection Kit |
| Chiesi USA, INC. | $14.26 | 2023 | Cleviprex, Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Humes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.